Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013522 | 0.92 | CNR1 (0.44) | PPARGALDH1A1NR1I2MAPTNAMPT | |
| SCHEMBL5010706 | 0.90 | PPARG (0.47) | PPARGNPC1RAB9ANR1I2MAPT | |
| SCHEMBL5010891 | 0.90 | CCR1 (0.45) | PPARGALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL5008275 | 0.89 | MAPT (0.48) | PPARGALDH1A1NPC1RAB9ANR1I2 | |
| SCHEMBL5010546 | 0.89 | PPARG (0.48) | PPARGNR1H4 | |
| SCHEMBL5008508 | 0.89 | GAA (0.45) | PPARGNPC1RAB9ANR1I2MAPT | |
| SCHEMBL5012114 | 0.89 | PPARG (0.45) | PPARGNR1I2NR1H4 | |
| SCHEMBL5012304 | 0.88 | PPARG (0.45) | PPARGNR1I2NR1H4 | |
| SCHEMBL5013431 | 0.88 | NPC1 (0.49) | PPARGNPC1RAB9ANR1I2MAPT | |
| SCHEMBL5008489 | 0.88 | PPARG (0.51) | PPARGNPC1RAB9ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | PPARG 706/4885ALDH1A1 1278/4885NPC1 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.